What Next for Aeglea Bio Therapeutics Inc (AGLE) Stock After Reaching 52-Week Low?

June 9, 2017 - By Hazel Jackson

The stock of Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) hit a new 52-week low and has $3.49 target or 4.00 % below today’s $3.64 share price. The 5 months bearish chart indicates high risk for the $48.30M company. The 1-year low was reported on Jun, 9 by Barchart.com. If the $3.49 price target is reached, the company will be worth $1.93M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

It is 0.00% or $0 reaching $3.64 per share. It is down 11.96% since June 9, 2016 and is downtrending. It has underperformed by 28.66% the S&P500.

Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) Ratings Coverage

Among 4 analysts covering Aeglea BioTherapeutics (NASDAQ:AGLE), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aeglea BioTherapeutics had 4 analyst reports since May 2, 2016 according to SRatingsIntel. The firm earned “Outperform” rating on Monday, May 2 by BMO Capital Markets. The stock of Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) has “Buy” rating given on Monday, May 2 by UBS. As per Monday, May 2, the company rating was initiated by Wells Fargo. The stock of Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) earned “Buy” rating by Needham on Monday, May 9.

More notable recent Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) news were published by: Seekingalpha.com which released: “Aeglea BioTherapeutics’ (AGLE) CEO David Lowe on Q4 2016 Results – Earnings …” on March 24, 2017, also Seekingalpha.com with their article: “Aeglea Biotherapeutics: Interesting Early-Stage Enzyme Therapy” published on March 08, 2017, Marketwatch.com published: “3.64” on June 21, 2015. More interesting news about Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) were released by: Globenewswire.com and their article: “Aeglea BioTherapeutics Prices Public Offering of Common Stock” published on June 05, 2017 as well as Reuters.com‘s news article titled: “BRIEF-Aeglea Biotherapeutics Q1 revenue $1.0 mln vs $900000” with publication date: May 09, 2017.

Aeglea BioTherapeutics, Inc. is a biotechnology company, which is engaged in the development of enzyme therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. The company has market cap of $48.30 million. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. It currently has negative earnings. The Company’s lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.